08:35 AM EDT, 08/26/2025 (MT Newswires) -- Inovio Pharmaceuticals ( INO ) said Tuesday that the US Food and Drug Administration has agreed to a rolling submission timeline for the biologics license application for its drug candidate INO-3107 to treat adults with recurrent respiratory papillomatosis.

The biotech company said it will submit its BLA and request a priority review in the coming months, and aims to file the application by the end of the year.

Shares of Inovio Pharmaceuticals ( INO ) were up 2.6% in recent premarket activity.